tetano
Editor, Senior Moderator
F1000Res. 2020 Apr 28;9. pii: F1000 Faculty Rev-305. doi: 10.12688/f1000research.22611.1. eCollection 2020.
Recent advances in influenza vaccines.
Pawelec G[SUP]1,[/SUP][SUP]2[/SUP], McElhaney J[SUP]2[/SUP].
Author information
Abstract
Seasonal influenza remains a major public health problem, responsible for hundreds of thousands of deaths every year, mostly of elderly people. Despite the wide availability of vaccines, there are multiple problems decreasing the effectiveness of vaccination programs. These include viral variability and hence the requirement to match strains by estimating which will become prevalent each season, problems associated with vaccine and adjuvant production, and the route of administration as well as the perceived lower vaccine efficiency in older adults. Clinical protection is still suboptimal for all of these reasons, and vaccine uptake remains too low in most countries. Efforts to improve the effectiveness of influenza vaccines include developing universal vaccines independent of the circulating strains in any particular season and stimulating cellular as well as humoral responses, especially in the elderly. This commentary assesses progress over the last 3 years towards achieving these aims. Since the beginning of 2020, an unprecedented international academic and industrial effort to develop effective vaccines against the new coronavirus SARS-CoV-2 has diverted attention away from influenza, but many of the lessons learned for the one will synergize with the other to mutual advantage. And, unlike the SARS-1 epidemic and, we hope, the SARS-CoV-2 pandemic, influenza will not be eliminated and thus efforts to improve influenza vaccines will remain of crucial importance.
Copyright: ? 2020 Pawelec G and McElhaney J.
KEYWORDS:
adjuvant; effectiveness; elderly; influenza; vaccine
PMID:32399192PMCID:PMC7194468DOI:10.12688/f1000research.22611.1
Free PMC Article
Recent advances in influenza vaccines.
Pawelec G[SUP]1,[/SUP][SUP]2[/SUP], McElhaney J[SUP]2[/SUP].
Author information
Abstract
Seasonal influenza remains a major public health problem, responsible for hundreds of thousands of deaths every year, mostly of elderly people. Despite the wide availability of vaccines, there are multiple problems decreasing the effectiveness of vaccination programs. These include viral variability and hence the requirement to match strains by estimating which will become prevalent each season, problems associated with vaccine and adjuvant production, and the route of administration as well as the perceived lower vaccine efficiency in older adults. Clinical protection is still suboptimal for all of these reasons, and vaccine uptake remains too low in most countries. Efforts to improve the effectiveness of influenza vaccines include developing universal vaccines independent of the circulating strains in any particular season and stimulating cellular as well as humoral responses, especially in the elderly. This commentary assesses progress over the last 3 years towards achieving these aims. Since the beginning of 2020, an unprecedented international academic and industrial effort to develop effective vaccines against the new coronavirus SARS-CoV-2 has diverted attention away from influenza, but many of the lessons learned for the one will synergize with the other to mutual advantage. And, unlike the SARS-1 epidemic and, we hope, the SARS-CoV-2 pandemic, influenza will not be eliminated and thus efforts to improve influenza vaccines will remain of crucial importance.
Copyright: ? 2020 Pawelec G and McElhaney J.
KEYWORDS:
adjuvant; effectiveness; elderly; influenza; vaccine
PMID:32399192PMCID:PMC7194468DOI:10.12688/f1000research.22611.1
Free PMC Article